

Colin P Dinney

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6687651/colin-p-dinney-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

342
papers

17,941
citations

73
h-index

118
g-index

368
ext. papers

20,907
ext. citations

4.9
avg, IF

6.21
L-index

#	Paper	IF	Citations
342	Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. <i>Cancer Cell</i> , 2014 , 25, 152-65	24.3	977
341	A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. <i>Nature Genetics</i> , 2010 , 42, 978-84	36.3	408
340	miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. <i>Clinical Cancer Research</i> , 2009 , 15, 5060-72	12.9	353
339	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020 , 77, 420-433	10.2	309
338	STAGE SPECIFIC GUIDELINES FOR SURVEILLANCE AFTER RADICAL NEPHRECTOMY FOR LOCAL RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 1998 , 159, 1163-1167	2.5	286
337	Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. <i>Cancer and Metastasis Reviews</i> , 2009 , 28, 335-44	9.6	272
336	Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. <i>Nature Genetics</i> , 2009 , 41, 991-5	36.3	270
335	Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. <i>Journal of Clinical Oncology</i> , 2001 , 19, 4005-13	2.2	250
334	Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. <i>American Journal of Human Genetics</i> , 2006 , 78, 464-79	11	234
333	Focus on bladder cancer. <i>Cancer Cell</i> , 2004 , 6, 111-6	24.3	221
332	Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. <i>Cancer</i> , 2007 , 110, 62-7	6.4	220
331	Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. <i>Cancer Research</i> , 2008 , 68, 2530-7	10.1	215
330	Clinical model of lifetime cost of treating bladder cancer and associated complications. <i>Urology</i> , 2006 , 68, 549-53	1.6	209
329	Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus. <i>Annals of Thoracic Surgery</i> , 1997 , 63, 1592-600	2.7	206
328	Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2014 , 11, 400-10	5.5	189
327	The Efficacy and Complications of Salvage Cryotherapy of the Prostate. <i>Journal of Urology</i> , 1997 , 157, 921-925	2.5	188
326	Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. <i>Journal of Urology</i> , 2004 , 172, 481-4	2.5	180

325	Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. <i>European Urology</i> , 2015 , 67, 241-9	10.2	178
324	The impact of variant histology on the outcome of bladder cancer treated with curative intent. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009 , 27, 3-7	2.8	176
323	Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. <i>Cancer</i> , 2010 , 116, 3127-34	6.4	174
322	Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. <i>EBioMedicine</i> , 2016 , 12, 105-117	8.8	169
321	The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. <i>Journal of Urology</i> , 2006 , 175, 881-5	2.5	165
320	A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. <i>European Urology</i> , 2014 , 66, 855-66	10.2	163
319	Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010 , 28, 429-40	2.8	160
318	Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. <i>Journal of Urology</i> , 2010 , 183, 2165-70	2.5	159
317	Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. <i>American Journal of Pathology</i> , 2001 , 158, 735-43	5.8	151
316	Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. <i>Journal of Clinical Oncology</i> , 2008 , 26, 121-6	2.2	148
315	Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. <i>BJU International</i> , 2011 , 107, 898-904	5.6	136
314	Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. <i>Cancer</i> , 2014 , 120, 1794-9	6.4	132
313	Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. <i>Journal of Urology</i> , 1998 , 159, 394-8	2.5	130
312	Isolation and Characterization of Metastatic Variants from Human Transitional Cell Carcinoma Passaged by Orthotopic Implantation in Athymic Nude Mice. <i>Journal of Urology</i> , 1995 , 154, 1532-1538	2.5	129
311	Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. <i>European Urology</i> , 2010 , 57, 300-9	10.2	127
310	Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5746-56	2.2	123
309	Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. <i>Journal of Urology</i> , 2014 , 191, 40-7	2.5	122
308	Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2592-7	2.2	120

307	Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2247-53	2.2	120
306	ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. <i>European Urology</i> , 2013 , 63, 36-44	10.2	117
305	Correlation between annual volume of cystectomy, professional staffing, and outcomes: a statewide, population-based study. <i>Cancer</i> , 2005 , 104, 975-84	6.4	117
304	International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. <i>BJU International</i> , 2010 , 105, 1402-12	5.6	114
303	Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. <i>Journal of Urology</i> , 2007 , 178, 2302-6; discussion 2307	2.5	112
302	Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. <i>Journal of Urology</i> , 2006 , 175, 2058-62	2.5	109
301	Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. <i>Journal of Urology</i> , 2013 , 189, 1656-61	2.5	107
300	The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. <i>Clinical Cancer Research</i> , 2010 , 16, 4461-7	12.9	107
299	Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. <i>European Urology</i> , 2013 , 64, 307-13	10.2	106
298	Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm?. <i>BJU International</i> , 2006 , 98, 1176-80	5.6	104
297	Origins of Bladder Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2016 , 11, 149-74	34	101
296	Genome-wide association study identifies multiple loci associated with bladder cancer risk. <i>Human Molecular Genetics</i> , 2014 , 23, 1387-98	5.6	101
295	Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. <i>Cancer Research</i> , 2005 , 65, 4902-8	10.1	101
294	Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. <i>Clinical Cancer Research</i> , 2003 , 9, 3167-75	12.9	101
293	The p63 protein isoform $\Delta Np63$ inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205. <i>Journal of Biological Chemistry</i> , 2013 , 288, 3275-88	5.4	95
292	Bladder cancer angiogenesis and metastasis--translation from murine model to clinical trial. <i>Cancer and Metastasis Reviews</i> , 2007 , 26, 623-34	9.6	95
291	Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 1635-42	2.8	92
290	Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. <i>European Urology</i> , 2016 , 70, 611-620	10.2	92

289	Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin. <i>European Urology</i> , 2016 , 69, 197-200 ²	10.2	91
288	Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. <i>Urology</i> , 2007 , 70, 252-6	1.6	90
287	Intravesical rAd-IFN γ /Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3410-3416	2.2	86
286	Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. <i>Clinical Cancer Research</i> , 2008 , 14, 1478-86	12.9	85
285	Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. <i>Journal of Urology</i> , 2006 , 176, 1463-7	2.5	85
284	Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 1408-15	12.9	83
283	The Risk of Upper Tract Recurrence Following Cystectomy in Patients with Transitional Cell Carcinoma Involving the Distal Ureter. <i>Journal of Urology</i> , 1996 , 155, 501-503	2.5	83
282	A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. <i>Human Molecular Genetics</i> , 2011 , 20, 4282-9 ^{5.6}	5.6	82
281	The stabilization and targeting of surfactant-synthesized gold nanorods. <i>Nanotechnology</i> , 2009 , 20, 434005	9.4	82
280	High-order interactions among genetic variants in DNA base excision repair pathway genes and smoking in bladder cancer susceptibility. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 84-9 ⁴	9.4	81
279	Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. <i>Journal of Urology</i> , 2006 , 176, 53-7; discussion 57	2.5	80
278	New strategies in muscle-invasive bladder cancer: on the road to personalized medicine. <i>Clinical Cancer Research</i> , 2011 , 17, 2608-12	12.9	79
277	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. <i>Human Molecular Genetics</i> , 2014 , 23, 6616-33	5.6	77
276	Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria. <i>Journal of Urology</i> , 2010 , 183, 929-34	2.5	77
275	Phase I trial of intravesical recombinant adenovirus mediated interferon- γ formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer. <i>Journal of Urology</i> , 2013 , 190, 850-6	2.5	76
274	Age and body mass index are independent risk factors for the development of postoperative paralytic ileus after radical cystectomy. <i>Urology</i> , 2010 , 76, 1419-24	1.6	76
273	Genetic instability in bladder cancer assessed by the comet assay. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 540-7	9.7	76
272	Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?. <i>Journal of Urology</i> , 2003 , 169, 2113-7	2.5	75

271	The Relationship of Local Control to Distant Metastasis in Muscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 1995 , 154, 2059-2064	2.5	75
270	Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003 , 21, 327-33	2.8	74
269	Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. <i>Cancer Research</i> , 2007 , 67, 1430-5	10.1	73
268	Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. <i>Nature Medicine</i> , 2020 , 26, 1845-1851	50.5	72
267	Plasma microRNA profiles for bladder cancer detection. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 1701-8	2.8	71
266	Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. <i>Cancer Research</i> , 2005 , 65, 10524-35	10.1	71
265	Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. <i>Journal of Urology</i> , 2011 , 185, 456-61	2.5	70
264	Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. <i>Carcinogenesis</i> , 2009 , 30, 2047-52	4.6	70
263	Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. <i>Cancer</i> , 2007 , 110, 764-9	6.4	70
262	Targeted therapies in bladder cancer--an update. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007 , 25, 433-8	2.8	70
261	Clinical outcomes of cT1 micropapillary bladder cancer. <i>Journal of Urology</i> , 2015 , 193, 1129-34	2.5	69
260	Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. <i>Urology</i> , 2014 , 83, 863-7	1.6	69
259	Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. <i>Journal of Urology</i> , 2004 , 171, 570-4	2.5	67
258	Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. <i>Journal of Urology</i> , 2008 , 179, 353-8	2.5	66
257	Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. <i>Journal of Urology</i> , 2007 , 178, 1492-6	2.5	66
256	Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 1245-54	6.1	65
255	Upper urinary tract tumors with nontransitional histology: a single-center experience. <i>Urology</i> , 2006 , 67, 518-23	1.6	65
254	Risk of Urethral, Vaginal and Cervical Involvement in Patients Undergoing Radical Cystectomy for Bladder Cancer: Results of a Contemporary Cystectomy Series from M. D. Anderson Cancer Center. <i>Journal of Urology</i> , 1997 , 157, 2120-2123	2.5	64

253	Modulation of DNA damage/DNA repair capacity by XPC polymorphisms. <i>DNA Repair</i> , 2008 , 7, 141-8	4.3	64
252	Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. <i>Cancer Research</i> , 2004 , 64, 8973-9	10.1	64
251	A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. <i>Cancer</i> , 2013 , 119, 540-7	6.4	63
250	Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 1401-11	9.7	63
249	Projecting individualized probabilities of developing bladder cancer in white individuals. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4974-81	2.2	63
248	Dietary isothiocyanates, GSTM1, GSTT1, NAT2 polymorphisms and bladder cancer risk. <i>International Journal of Cancer</i> , 2007 , 120, 2208-13	7.5	62
247	Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5528-35	2.2	62
246	Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. <i>Clinical Cancer Research</i> , 2002 , 8, 1258-70	12.9	62
245	The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 279-90	6.1	62
244	Matrix metalloproteinase polymorphisms and bladder cancer risk. <i>Cancer Research</i> , 2006 , 66, 11644-8	10.1	61
243	High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. <i>Carcinogenesis</i> , 2007 , 28, 2160-5	4.6	61
242	A genome-wide association study identifies a locus on chromosome 14q21 as a predictor of leukocyte telomere length and as a marker of susceptibility for bladder cancer. <i>Cancer Prevention Research</i> , 2011 , 4, 514-21	3.2	60
241	Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG. <i>Bladder Cancer</i> , 2015 , 1, 29-30	1	59
240	p63 expression defines a lethal subset of muscle-invasive bladder cancers. <i>PLoS ONE</i> , 2012 , 7, e30206	3.7	58
239	Cancer risk associated with chronic diseases and disease markers: prospective cohort study. <i>BMJ, The</i> , 2018 , 360, k134	5.9	57
238	A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. <i>BJU International</i> , 2007 , 100, 1377-84	5.6	57
237	Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. <i>Clinical Cancer Research</i> , 2006 , 12, 4671-7	12.9	56
236	Molecular correlates of gefitinib responsiveness in human bladder cancer cells. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 277-85	6.1	56

235	Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. <i>Molecular Therapy</i> , 2004 , 10, 525-32	11.7	56
234	Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial. <i>Journal of Urology</i> , 2012 , 187, 862-7	2.5	55
233	Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting. <i>PLoS ONE</i> , 2013 , 8, e57284	3.7	55
232	Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. <i>Laboratory Investigation</i> , 2008 , 88, 694-721	5.9	55
231	The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. <i>Clinical Cancer Research</i> , 2002 , 8, 1863-70	12.9	55
230	Urachal carcinoma: a pathologic and clinical study of 46 cases. <i>Human Pathology</i> , 2015 , 46, 1808-14	3.7	54
229	Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 224-9	12.9	54
228	Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. <i>Cell Reports</i> , 2019 , 27, 1781-1793.e4	10.6	53
227	Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. <i>Urology</i> , 2009 , 73, 147-52	1.6	53
226	Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. <i>Lancet Oncology</i> , 2021 , 22, 107-117	21.7	53
225	Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. <i>Carcinogenesis</i> , 2010 , 31, 1387-91	4.6	52
224	Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. <i>Journal of Urology</i> , 2010 , 184, 888-94	2.5	52
223	pT0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. <i>European Urology</i> , 2007 , 52, 769-74	10.2	52
222	Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. <i>Clinical Cancer Research</i> , 2007 , 13, 2614-20	12.9	52
221	Review of the M.D. Anderson experience in the treatment of bladder sarcoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007 , 25, 38-45	2.8	52
220	Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with penile carcinoma. <i>BJU International</i> , 2013 , 111, 1068-74	5.6	51
219	Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. <i>BJU International</i> , 2011 , 108, 1119-23	5.6	51
218	Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. <i>Journal of Urology</i> , 2010 , 183, 87-93	2.5	50

217	Self-assembled fluorescent magnetic nanoprobes for multimode-biomedical imaging. <i>Biomaterials</i> , 2010 , 31, 9310-9	15.6	50
216	Clinical presentation and outcome of high-grade urinary bladder leiomyosarcoma in adults. <i>Urology</i> , 2003 , 61, 1151-5	1.6	50
215	Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. <i>Cancer Gene Therapy</i> , 2002 , 9, 687-91	5.4	49
214	Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop. <i>Urology</i> , 2014 , 83, 262-4	1.6	48
213	Robot assisted extended pelvic lymphadenectomy at radical cystectomy: lymph node yield compared with second look open dissection. <i>Journal of Urology</i> , 2011 , 185, 79-83	2.5	48
212	Bladder cancer: narrowing the gap between evidence and practice. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5680-4	2.2	47
211	RELATIONSHIP AMONG CYSTECTOMY, MICROVESSEL DENSITY AND PROGNOSIS IN STAGE T1 TRANSITIONAL CELL CARCINOMA OF THE BLADDER. <i>Journal of Urology</i> , 1998 , 160, 1285-1290	2.5	46
210	Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015 , 29, 377-94, x-xi	3.1	45
209	Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. <i>Cancer</i> , 2008 , 112, 2467-74	6.4	45
208	Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. <i>Clinical Cancer Research</i> , 2008 , 14, 2236-44	12.9	44
207	Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells. <i>Cancer Biology and Therapy</i> , 2007 , 6, 872-9	4.6	44
206	Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. <i>Cancer Research</i> , 2004 , 64, 4601-10	10.1	44
205	Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer. <i>Cancer</i> , 2010 , 116, 340-6	6.4	43
204	Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer. <i>Cancer Prevention Research</i> , 2010 , 3, 1235-45	3.2	42
203	Significance of upper urinary tract urothelial thickening and filling defect seen on MDCT urography in patients with a history of urothelial neoplasms. <i>American Journal of Roentgenology</i> , 2010 , 195, 959-65	5.4	42
202	Nephrectomy and vena caval thrombectomy in patients with metastatic renal cell carcinoma. <i>Urology</i> , 1997 , 50, 673-7	1.6	42
201	Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. <i>Laboratory Investigation</i> , 2005 , 85, 532-49	5.9	42
200	Squamous cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 16 cases. <i>Human Pathology</i> , 2009 , 40, 1448-52	3.7	41

199	Rationale for bladder-sparing surgery in patients with locally advanced colorectal carcinoma. <i>Cancer</i> , 1999 , 86, 2212-6	6.4	41
198	Differential expression of GATA-3 in urothelial carcinoma variants. <i>Human Pathology</i> , 2014 , 45, 1466-72	3.7	40
197	Urinary nuclear matrix protein 22 (NMP22): a diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladder. <i>Diagnostic Cytopathology</i> , 1999 , 20, 285-90	1.4	40
196	Micropapillary bladder cancer: current treatment patterns and review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 826-32	2.8	39
195	Growth factors and receptors as prognostic markers in urothelial carcinoma. <i>Current Urology Reports</i> , 2008 , 9, 55-61	2.9	39
194	Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. <i>Clinical Cancer Research</i> , 2020 , 26, 882-891	12.9	39
193	Underutilization of Radical Cystectomy Among Patients Diagnosed with Clinical Stage T2 Muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2017 , 3, 258-264	5.1	38
192	Dietary intake of vegetables and fruits and the modification effects of GSTM1 and NAT2 genotypes on bladder cancer risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 2090-7	4	38
191	Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. <i>Urology</i> , 2011 , 78, 61-7	1.6	37
190	Clinical model of cost of bladder cancer in the elderly. <i>Urology</i> , 2008 , 71, 519-25	1.6	37
189	Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 49 Cases. <i>American Journal of Clinical Pathology</i> , 2017 , 147, 500-506	1.9	36
188	Genome-wide association study identifies variants in casein kinase II (CSNK2A2) to be associated with leukocyte telomere length in a Punjabi Sikh diabetic cohort. <i>Circulation: Cardiovascular Genetics</i> , 2014 , 7, 287-95		36
187	Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer. <i>Carcinogenesis</i> , 2007 , 28, 698-703	4.3	36
186	Organ preservation for muscle-invasive bladder cancer by transurethral resection. <i>Urology</i> , 2007 , 70, 473-6	1.6	35
185	Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction. <i>Journal of Urology</i> , 2008 , 180, 164-7; discussion 167	2.5	34
184	Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 59.e1-8	2.8	33
183	Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. <i>American Journal of Clinical Pathology</i> , 2014 , 142, 864-71	1.9	33
182	Upper tract urothelial carcinoma: impact of time to surgery. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012 , 30, 266-72	2.8	33

181	Personal permanent hair dye use is not associated with bladder cancer risk: evidence from a case-control study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 1746-9	4	32
180	Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior. <i>Scientific Reports</i> , 2017 , 7, 40714	4.9	31
179	Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis. <i>BJU International</i> , 2010 , 106, 1799-804	5.6	31
178	Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003 , 21, 456-62	2.8	31
177	Genetic Variants in the Wnt/ β Catenin Signaling Pathway as Indicators of Bladder Cancer Risk. <i>Journal of Urology</i> , 2015 , 194, 1771-6	2.5	30
176	Urine cell-based DNA methylation classifier for monitoring bladder cancer. <i>Clinical Epigenetics</i> , 2018 , 10, 71	7.7	30
175	Inhibition of inducible heat shock protein-70 (hsp72) enhances bortezomib-induced cell death in human bladder cancer cells. <i>PLoS ONE</i> , 2013 , 8, e69509	3.7	30
174	Vitamins C and K3 sensitize human urothelial tumors to gemcitabine. <i>Journal of Urology</i> , 2006 , 176, 1642-7	3.5	30
173	Therapy of invasive bladder cancer. <i>Urology</i> , 2006 , 67, 56-9; discussion 60-1	1.6	30
172	Bladder cancer risk as modified by family history and smoking. <i>Cancer</i> , 2006 , 107, 705-11	6.4	29
171	Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. <i>Journal of Urology</i> , 2006 , 176, 787-92	2.5	29
170	Genetic subtypes of invasive bladder cancer. <i>Current Opinion in Urology</i> , 2015 , 25, 449-58	2.8	28
169	A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer. <i>Cancer</i> , 2010 , 116, 4513-9	6.4	28
168	Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 3032-41	6.1	28
167	Complications of radical cystectomy: impact of the timing of perioperative chemotherapy. <i>Urology</i> , 1996 , 47, 826-30	1.6	28
166	Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer. <i>Oncotarget</i> , 2016 , 7, 80164-80174	3.3	28
165	Energy balance, the PI3K-AKT-mTOR pathway genes, and the risk of bladder cancer. <i>Cancer Prevention Research</i> , 2010 , 3, 505-17	3.2	27
164	Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. <i>Journal of Urology</i> , 2011 , 185, 1216-21	2.5	27

163	The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. <i>Neoplasia</i> , 2005 , 7, 912-20	6.4	27
162	Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. <i>Human Pathology</i> , 2018 , 79, 57-65	3.7	27
161	Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies. <i>BJU International</i> , 2016 , 117, 754-60	5.6	26
160	Plasma vitamins E and A and risk of bladder cancer: a case-control analysis. <i>Cancer Causes and Control</i> , 2008 , 19, 981-92	2.8	26
159	ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2019 , 37, 51-60	4	25
158	Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 480-6	2.8	25
157	Genetic Variations in Glutathione Pathway Genes Predict Cancer Recurrence in Patients Treated with Transurethral Resection and Bacillus Calmette-Guérin Instillation for Non-muscle Invasive Bladder Cancer. <i>Annals of Surgical Oncology</i> , 2015 , 22, 4104-10	3.1	24
156	Assessment of Luminal and Basal Phenotypes in Bladder Cancer. <i>Scientific Reports</i> , 2020 , 10, 9743	4.9	24
155	Hiding in plain view: genetic profiling reveals decades old cross contamination of bladder cancer cell line KU7 with HeLa. <i>Journal of Urology</i> , 2013 , 190, 1404-9	2.5	24
154	Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. <i>BJU International</i> , 2017 , 119, 684-691	5.6	24
153	Neoadjuvant chemotherapy for bladder cancer. <i>World Journal of Urology</i> , 2006 , 24, 531-42	4	24
152	Genetic polymorphism in bladder cancer. <i>Frontiers in Bioscience - Landmark</i> , 2007 , 12, 192-213	2.8	24
151	Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 1108-15	2.8	23
150	Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy. <i>World Journal of Urology</i> , 2012 , 30, 753-9	4	23
149	The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012 , 30, 821-4	2.8	23
148	Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-Guérin. <i>PLoS ONE</i> , 2012 , 7, e38533	3.7	23
147	Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells. <i>Cancer Biology and Therapy</i> , 2012 , 13, 1325-38	4.6	23
146	Surveillance and management of recurrence for upper tract transitional cell carcinoma. <i>Urologic Clinics of North America</i> , 2003 , 30, 791-802	2.9	23

145	Summary and Recommendations from the National Cancer Institute Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016 , 2, 165-202 ¹		22
144	Fluid intake, genetic variants of UDP-glucuronosyltransferases, and bladder cancer risk. <i>British Journal of Cancer</i> , 2013 , 108, 2372-80	8.7	22
143	Genetic variations in micro-RNA biogenesis genes and clinical outcomes in non-muscle-invasive bladder cancer. <i>Carcinogenesis</i> , 2013 , 34, 1006-11	4.6	22
142	Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. <i>Journal of Endourology</i> , 2017 , 31, 946-953	2.7	22
141	Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer. <i>Journal of Urology</i> , 2011 , 185, 693-700	2.5	22
140	Should cystectomy only be performed at high-volume hospitals by high-volume surgeons?. <i>Current Opinion in Urology</i> , 2006 , 16, 344-9	2.8	22
139	Adenoviral-mediated gene therapy of human bladder cancer with antisense interleukin-8. <i>Oncology Reports</i> , 2001 , 8, 955-64	3.5	22
138	Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. <i>Human Molecular Genetics</i> , 2016 , 25, 1203-14	5.6	20
137	Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease. <i>European Urology</i> , 2019 , 75, 8-10	10.2	20
136	Patient-Reported Outcomes Are Associated With Enhanced Recovery Status in Patients With Bladder Cancer Undergoing Radical Cystectomy. <i>Surgical Innovation</i> , 2018 , 25, 242-250	2	19
135	Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2019 , 13, 24-28	1.2	19
134	Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvant therapies after radical cystectomy. <i>BJU International</i> , 2012 , 110, E590-5	5.6	19
133	Intake of red meat and heterocyclic amines, metabolic pathway genes and bladder cancer risk. <i>International Journal of Cancer</i> , 2012 , 131, 1892-903	7.5	19
132	Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. <i>BJU International</i> , 2011 , 108, 687-92	5.6	19
131	Management of urethral recurrence after orthotopic urinary diversion. <i>BJU International</i> , 2010 , 106, 56-61	5.6	19
130	Risk factors for falls in older patients with cancer. <i>BMJ Supportive and Palliative Care</i> , 2018 , 8, 34-37	2.2	18
129	Genetic variations in the transforming growth factor beta pathway as predictors of bladder cancer risk. <i>PLoS ONE</i> , 2012 , 7, e51758	3.7	18
128	Intrinsic subtypes and bladder cancer metastasis. <i>Asian Journal of Urology</i> , 2016 , 3, 260-267	2.7	18

127	Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery. <i>Urologia Internationalis</i> , 2011 , 87, 42-8	1.9	17
126	Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design. <i>European Urology</i> , 2016 , 70, 778-785	10.2	17
125	Cost-Effectiveness of Robot-assisted Radical Cystectomy Using a Propensity-matched Cohort. <i>European Urology Focus</i> , 2020 , 6, 88-94	5.1	17
124	Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer. <i>Journal of Urology</i> , 2007 , 177, 1900-6	2.5	16
123	Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era. <i>Cancer</i> , 2006 , 107, 1491-5	6.4	16
122	Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach?. <i>Urology</i> , 2006 , 67, 466-71	1.6	16
121	Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE). <i>Current Opinion in Urology</i> , 2004 , 14, 295-300	2.8	16
120	Efficient therapeutic gene delivery after systemic administration of a novel polyethylenimine/DNA vector in an orthotopic bladder cancer model. <i>Cancer Research</i> , 2003 , 63, 4017-20	10.1	16
119	Mitochondrial DNA Content as Risk Factor for Bladder Cancer and Its Association with Mitochondrial DNA Polymorphisms. <i>Cancer Prevention Research</i> , 2015 , 8, 607-13	3.2	15
118	Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomy. <i>Urology</i> , 2014 , 84, 1147-51	1.6	15
117	THE WILLET F. WHITMORE, JR., LECTURESHIP: BLOCKADE OF EPIDERMAL GROWTH FACTOR RECEPTORS AS ANTICANCER THERAPY. <i>Journal of Urology</i> , 2001 , 165, 1152-1157	2.5	15
116	Genetic variants in telomere-maintenance genes and bladder cancer risk. <i>PLoS ONE</i> , 2012 , 7, e30665	3.7	15
115	The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 3.e17-3.e27	2.8	15
114	Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. <i>Cell Reports</i> , 2019 , 26, 2241-2256.e4	10.6	15
113	Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy. <i>Surgery</i> , 2017 , 161, 1246-1254	3.6	14
112	Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. <i>European Urology Focus</i> , 2018 , 4, 720-724	5.1	14
111	Clinical significance of ureteric skip lesions at the time of radical cystectomy: the M.D. Anderson experience and literature review. <i>BJU International</i> , 2014 , 113, E28-33	5.6	14
110	p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells. <i>Cancer Biology and Therapy</i> , 2012 , 13, 477-86	4.6	14

109	The pharmacogenetic impact of inflammatory genes on bladder cancer recurrence. <i>Pharmacogenomics</i> , 2005 , 6, 575-84	2.6	14
108	INTERLEUKIN-8 (IL-8) EXPRESSION REGULATES TUMORIGENICITY AND METASTASIS IN HUMAN BLADDER CANCER. <i>Journal of Urology</i> , 1999 , 120	2.5	14
107	High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis. <i>Oncolmmunology</i> , 2017 , 6, e1265719	7.2	13
106	Risk assessment of renal cell carcinoma using alkaline comet assay. <i>Cancer</i> , 2007 , 110, 282-8	6.4	13
105	Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon β Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer. <i>Annals of Surgical Oncology</i> , 2016 , 23, 4110-4114	3.1	13
104	Is folic acid safe for non-muscle-invasive bladder cancer patients? An evidence-based cohort study. <i>American Journal of Clinical Nutrition</i> , 2018 , 107, 208-216	7	12
103	Comprehensive pathway-based interrogation of genetic variations in the nucleotide excision DNA repair pathway and risk of bladder cancer. <i>Cancer</i> , 2012 , 118, 205-15	6.4	12
102	The role of radical cystectomy in patients with clinical T4b bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011 , 29, 157-61	2.8	12
101	Cardiac history and risk of post-cystectomy cardiac complications. <i>Urology</i> , 2009 , 74, 1085-9	1.6	12
100	EVIDENCE-BASED GENDER RELATED OUTCOMES AFTER RADICAL CYSTECTOMY: RESULTS OF A LARGE MULTICENTER STUDY. <i>Journal of Urology</i> , 2009 , 181, 629	2.5	12
99	Benzo(a)pyrene diol epoxide-induced chromosome 9p21 aberrations are associated with increased risk of bladder cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 2445-50	4	12
98	Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis. <i>Oncotarget</i> , 2017 , 8, 34205-34222	3.3	12
97	Overall survival in older patients with cancer. <i>BMJ Supportive and Palliative Care</i> , 2020 , 10, 25-35	2.2	12
96	Pathway analysis of bladder cancer genome-wide association study identifies novel pathways involved in bladder cancer development. <i>Genes and Cancer</i> , 2016 , 7, 229-239	2.9	11
95	Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration. <i>Drugs in R and D</i> , 2017 , 17, 297-304	3.4	10
94	Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. <i>European Urology Focus</i> , 2017 , 3, 577-583	5.1	10
93	Clinical and therapeutic significance of aberrant differentiation patterns in bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2007 , 7, 1015-26	3.5	10
92	Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer. <i>International Journal of Cancer</i> , 2018 , 142, 1797-1804	7.5	10

91	Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy. <i>BJU International</i> , 2018 , 122, 89-98	5.6	9
90	Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience. <i>Supportive Care in Cancer</i> , 2018 , 26, 1561-1568	3.9	8
89	Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index. <i>Journal of Geriatric Oncology</i> , 2018 , 9, 81-83	3.6	8
88	Detection of bladder cancer using proteomic profiling of urine sediments. <i>PLoS ONE</i> , 2012 , 7, e42452	3.7	8
87	The use of urine-based biomarkers in bladder cancer. <i>Urology</i> , 2006 , 67, 62-4	1.6	8
86	A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer. <i>SSRN Electronic Journal</i> ,	1	8
85	The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. <i>World Journal of Urology</i> , 2019 , 37, 2041-2049	4	8
84	Concepts for banking tissue in urologic oncology--the International Bladder Cancer Bank. <i>Clinical Cancer Research</i> , 2005 , 11, 413-5	12.9	8
83	Dose dense MVAC prior to radical cystectomy: a real-world experience. <i>World Journal of Urology</i> , 2017 , 35, 1729-1736	4	7
82	Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 639.e1-639.e9	2.8	7
81	Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 469-76	2.8	7
80	Ultrasound-guided transperineal needle biopsy of the prostate after abdominoperineal resection. <i>Journal of Clinical Ultrasound</i> , 1995 , 23, 263-5	1	7
79	Serum microRNAs as predictors of risk for non-muscle invasive bladder cancer. <i>Oncotarget</i> , 2018 , 9, 14895-14908	3.3	7
78	Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. <i>iScience</i> , 2020 , 23, 101206.1	6.1	7
77	Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation. <i>Onc Immunology</i> , 2019 , 8, e1577125	7.2	6
76	Office cystoscopy and transrectal ultrasound-guided prostate biopsies pose minimal risk: prospective evaluation of 921 procedures. <i>Urology</i> , 2009 , 73, 1175-8	1.6	6
75	Clinical applications for targeted therapy in bladder cancer. <i>Urologic Clinics of North America</i> , 2005 , 32, 239-46, vii	2.9	6
74	If cystectomy is insufficient, what is an urologist to do?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003 , 21, 475-8	2.8	6

73	Original Articles: Bladder Cancer: Management of Transitional Cell Carcinoma Involving Von Brunn's Nests. <i>Journal of Urology</i> , 1995 , 153, 944-949	2.5	6
72	The consensus molecular classification of muscle-invasive bladder cancer		6
71	Salvage topical therapy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2018 , 36, 2027-2034	4.4	6
70	The role of metastatic burden in cytoreductive/consolidative radical cystectomy. <i>World Journal of Urology</i> , 2019 , 37, 2691-2698	4	5
69	Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. <i>JAMA Oncology</i> , 2019 , 5, 1790-1798	13.4	5
68	Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer. <i>Bladder Cancer</i> , 2017 , 3, 145-146	1	5
67	Novel therapeutics for patients with non-muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2009 , 9, 807-13	3.5	5
66	Emerging drugs for targeted therapy of bladder cancer. <i>Expert Opinion on Emerging Drugs</i> , 2007 , 12, 435-48	3.7	5
65	Gene therapy for superficial bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2001 , 1, 531-9	3.5	5
64	Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design. <i>Journal of Urology</i> , 2021 , 205, 1612-1621	2.5	5
63	Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. <i>European Urology Oncology</i> , 2019 , 2, 286-293	6.7	5
62	Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer?. <i>Journal of Urology</i> , 2008 , 180, 1146-53	2.5	4
61	Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer. <i>Translational Andrology and Urology</i> , 2015 , 4, 273-82	2.3	4
60	1521: Variant Histology in Bladder Cancer - Experience in 1246 Patients Undergoing Cystectomy. <i>Journal of Urology</i> , 2007 , 177, 502-502	2.5	4
59	Intravesical Gene Therapy. <i>Urologic Clinics of North America</i> , 2020 , 47, 93-101	2.9	4
58	Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test. <i>European Urology Focus</i> , 2019 , 5, 664-675	5.1	4
57	Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. <i>Journal of Urology</i> , 2021 , 206, 548-557	2.5	4
56	Unique somatic variants in DNA from urine exosomes of individuals with bladder cancer. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021 , 22, 360-376	6.4	4

55	Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 354.e19-354.e26	2.8	3
54	The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guërin. <i>BJU International</i> , 2021 , 128, 65-71	5.6	3
53	Effects of thiazolidinedione in patients with active bladder cancer. <i>BJU International</i> , 2018 , 121, 244-251	5.6	3
52	Reply to Mattias Aine, Fredrik Liedberg, Gottfrid Sjöbahl, and Mattias Höglund Letter to the Editor re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New insights into subtypes of invasive bladder cancer: considerations of the clinician. <i>Eur Urol</i> 2014;66:609-10. <i>European Urology</i> , 2014 , 66, 609-10	10.2	3
51	Delayed ureterectomy after incomplete nephroureterectomy for upper tract urothelial carcinoma: pathologic findings and outcomes. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2013 , 39, 817-22	2	3
50	Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guërin. <i>Oncotarget</i> , 2017 , 8, 88782-88791	3.1	3
49	The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Guërin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data. <i>Journal of Urology</i> , 2020 , 203, 283-291	2.5	3
48	TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer. <i>Molecular Cancer Research</i> , 2020 , 18, 811-821	6.6	2
47	Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 247-254	2.8	2
46	Reply by the authors. <i>Urology</i> , 2014 , 84, 495-6	1.6	2
45	Uncommon Cancers of the Bladder 2012 , 23-33		2
44	Intelligent Clinical Decision Support Systems for Non-invasive Bladder Cancer Diagnosis. <i>Lecture Notes in Computer Science</i> , 2011 , 253-262	0.9	2
43	The International Bladder Cancer Network. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010 , 28, 375-6	2.8	2
42	The molecular, the bad, and the ugly: preventing bladder cancer via mTOR inhibition. <i>Cancer Prevention Research</i> , 2009 , 2, 1001-2	3.2	2
41	High risk populations and cystectomy outcomes. <i>Journal of Urology</i> , 2009 , 182, 10-1	2.5	2
40	Uncommon Cancers of the Bladder 2006 , 18-26		2
39	1240: Prospective Evidence Supporting the Utility of Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer: Preliminary Results from A Phase II Clinical Trial at the M.D. Anderson Cancer Center. <i>Journal of Urology</i> , 2006 , 175, 399-399	2.5	2
38	Bacillus Calmette-Guërin Salvage Therapy: Definitions and Context. <i>Urologic Clinics of North America</i> , 2020 , 47, 1-4	2.9	2

37	Revisiting an Old Conundrum: A Systematic Review and Meta-Analysis of Intravesical Therapy for Treatment of Urothelial Carcinoma of the Prostate. <i>Bladder Cancer</i> , 2021 , 7, 243-252	1	2
36	Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. <i>Journal of Urology</i> , 2021 , 206, 1258-1267	2.5	2
35	Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center. <i>World Journal of Urology</i> , 2021 , 39, 4143-4149	4	2
34	Bladder Cancer Involving Smooth Muscle of Indeterminate Type or Muscularis Mucosae in Transurethral Biopsy Specimens. <i>American Journal of Clinical Pathology</i> , 2020 , 154, 208-214	1.9	2
33	Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021 , 39, 4345-4354	4	2
32	Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy. <i>World Journal of Urology</i> , 2016 , 34, 695-701	4	1
31	Re: Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-sparing Trimodality Therapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2019 , 75, 1034-1035	10.2	1
30	Comparison between whole mount tissue preparations and virtual tissue microarray samples for measuring Ki-67 and apoptosis indices in human bladder cancer: A cross-sectional study. <i>Medicine (United States)</i> , 2016 , 95, e4500	1.8	1
29	Accuracy of High-Frequency Endoluminal Ultrasonography for Clinical Staging of Upper Tract Urothelial Carcinoma. <i>Journal of Endourology</i> , 2018 , 32, 806-811	2.7	1
28	High-grade neuroendocrine carcinoma of the urachus-report of 3 cases. <i>Human Pathology</i> , 2017 , 67, 1263-1268	3.3	1
27	Non-seminomatous germ cell tumor with bone metastasis only at diagnosis: A rare clinical presentation. <i>Asian Journal of Urology</i> , 2017 , 4, 124-127	2.7	1
26	Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease. <i>Bladder Cancer</i> , 2017 , 3, 147-148	1	1
25	Multilevel-analysis identify a cis-expression quantitative trait locus associated with risk of renal cell carcinoma. <i>Oncotarget</i> , 2015 , 6, 4097-109	3.3	1
24	Words of wisdom. Re: D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. <i>European Urology</i> , 2009 , 56, 745-6	10.2	1
23	A combination of intravesical BCG [corrected] and [corrected] electromotive mitomycin for high-risk superficial bladder cancer. <i>Nature Reviews Urology</i> , 2006 , 3, 472-3		1
22	Radical Cystectomy and Perioperative Sexual Function: A Cross-Sectional Analysis. <i>Journal of Sexual Medicine</i> , 2020 , 17, 1995-2004	1.1	1
21	Time interval from transurethral resection of bladder tumour to bacille Calmette-Guérin induction does not impact therapeutic response. <i>BJU International</i> , 2021 , 128, 634-641	5.6	1
20	Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 301.e17-301.e28	2.8	1

19	Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2021 , 79, 428-429	10.2	1
18	Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. <i>BJU International</i> , 2021 , 127, 528-537	5.6	1
17	Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer. <i>BJU International</i> , 2021 , 128, 568-574	5.6	1
16	Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2022 , 207, 70-76	2.5	1
15	Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma.. <i>BJUI Compass</i> , 2022 , 3, 37-44	0.9	0
14	Role of Lymphadenectomy during Radical Cystectomy for Nonmuscle-Invasive Bladder Cancer: Results from a Multi-Institutional Experience. <i>Journal of Urology</i> , 2021 , 101097JU00000000000002266	2.5	0
13	Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 237.e1-237.e5	2.8	0
12	Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. <i>Journal of Urology</i> , 2021 , 206, 577-585	2.5	0
11	Treatment Paradigms in Bladder Cancer: Clinical Implications of Histological and Molecular Analysis. <i>Molecular Pathology Library</i> , 2018 , 85-101		
10	Urological cancers. Preface. <i>Cancer and Metastasis Reviews</i> , 2009 , 28, 267	9.6	
9	Radical cystectomy: posterior dissection following prior therapy. <i>Journal of Surgical Oncology</i> , 1997 , 64, 165-6	2.8	
8	Bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008 , 26, 479-80	2.8	
7	Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter. <i>Bladder Cancer</i> , 2022 , 1-5	1	
6	Multi-targeted agents in the treatment of urothelial carcinoma353-361		
5	Boosted C5 Trees i-Biomarkers Panel for Invasive Bladder Cancer Progression Prediction. <i>Lecture Notes in Computer Science</i> , 2012 , 190-200	0.9	
4	Small Cell Urothelial Carcinoma 2012 , 173-181		
3	Reply by Authors. <i>Journal of Urology</i> , 2021 , 205, 1620-1621	2.5	
2	Oncologic Equipoise Between Robotic and Open Radical Cystectomy. <i>Journal of Endourology</i> , 2021 , 35, 1168-1176	2.7	

- 1 Reply by Authors. *Journal of Urology*, **2021**, 206, 1267 2.5